LncRNA AK023948 is a positive regulator of AKT

Nature Communications

Volumn 8, Issue , 2017, Pages

  Koirala, Pratirodh ^a   Huang, Jianguo ^a   Ho, Tsui Ting ^a,b   Wu, Fangting ^c   Ding, Xianfeng ^a,d   Mo, Yin Yuan ^a,b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c System Biosciences   (United States)

^d ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LONG UNTRANSLATED RNA; PROTEIN KINASE B; PROTEIN P85; DEAD BOX PROTEIN; DHX9 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; SMALL INTERFERING RNA; TUMOR PROTEIN;

CANCER; DATA SET; ENZYME ACTIVITY; GENE; PHYSIOLOGICAL RESPONSE; SURVIVAL; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CRISPR CAS SYSTEM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; UPREGULATION; ANIMAL; BREAST; BREAST TUMOR; DISEASE EXACERBATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE KNOCKOUT; GENETICS; MCF-7 CELL LINE; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY;

ANIMALS; BREAST; BREAST NEOPLASMS; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; CRISPR-CAS SYSTEMS; DEAD-BOX RNA HELICASES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; HUMANS; MCF-7 CELLS; MICE, NUDE; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, LONG NONCODING; RNA, SMALL INTERFERING; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85011982942     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14422     Document Type: Article

References (57)

1. Consortium, E. P. et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447, 799-816 (2007).
2. Tsai, M. C. et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 329, 689-693 (2010).
3. Kino, T. et al. gas5 is a growth arrest-and starvation-associated repressor of the glucocorticoid receptor. Sci. Signal. 3, ra8 (2010).
4. Zhang, Z. et al. Negative regulation of lncRNA GAS5 by miR-21. Cell Death Differ. 20, 1558-1568 (2013).
5. Mercer, T. R., Dinger, M. E. & Mattick, J. S. Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 10, 155-159 (2009).
6. Wang, K. C. & Chang, H. Y. Molecular mechanisms of long noncoding RNAs. Mol. Cell 43, 904-914 (2011).
7. Ulitsky, I. & Bartel, D. P. lincRNAs: genomics, evolution, and mechanisms. Cell 154, 26-46 (2013).
8. Hu, W., Alvarez-Dominguez, J. R. & Lodish, H. F. Regulation of mammalian cell differentiation by long non-coding RNAs. EMBO Rep. 13, 971-983 2012
9. Fresno Vara, J. A. et al. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30, 193-204 (2004).
10. Los, M., Maddika, S., Erb, B. & Schulze-Osthoff, K. Switching Akt: from survival signaling to deadly response. Bioessays 31, 492-495 (2009).
11. Vanhaesebroeck, B., Stephens, L. & Hawkins, P. PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 13, 195-203 2012
12. Hollander, M. C., Blumenthal, G. M. & Dennis, P. A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 11, 289-301 (2011).
13. Thorpe, L. M., Yuzugullu, H. & Zhao, J. J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15, 7-24 (2015).
14. Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583-588 (2015).
15. Maeder, M. L. et al. CRISPR RNA-guided activation of endogenous human genes. Nat. Methods 10, 977-979 (2013).
16. Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for sequencespecific control of gene expression. Cell 152, 1173-1183 (2013).
17. Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868 (1999).
18. Deuschle, U., Meyer, W. K. & Thiesen, H. J. Tetracycline-reversible silencing of eukaryotic promoters. Mol. Cell Biol. 15, 1907-1914 (1995).
19. Herchenroder, O., Hahne, J. C., Meyer, W. K., Thiesen, H. J. & Schneider, J. Repression of the human immunodeficiency virus type 1 promoter by the human KRAB domain results in inhibition of virus production. Biochim. Biophys. Acta 1445, 216-223 (1999).
20. Rittner, K., Schultz, H., Pavirani, A. & Mehtali, M. Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro. J. Virol. 71, 3307-3311 (1997).
21. He, H. et al. A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Res. 69, 625-631 (2009).
22. Ho, T. T. et al. Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. Nucleic Acids Res. 43, e17 (2015).
23. Nakata, T. & Suzuki, N. Chromogen-based immunohistochemical method for elucidation of the coexpression of two antigens using antibodies from the same species. J. Histochem. Cytochem. 60, 611-619 (2012).
24. Nuovo, G. J. In Situ Molecular Pathology and Co-expression Analyses (Academic Press, 2013).
25. Zhang, S. & Grosse, F. Domain structure of human nuclear DNA helicase II (RNA helicase A). J. Biol. Chem. 272, 11487-11494 (1997).
26. Tetsuka, T. et al. RNA helicase A interacts with nuclear factor kappaB p65 and functions as a transcriptional coactivator. Eur. J. Biochem. 271, 3741-3751 (2004).
27. Schlegel, B. P., Starita, L. M. & Parvin, J. D. Overexpression of a protein fragment of RNA helicase A causes inhibition of endogenous BRCA1 function and defects in ploidy and cytokinesis in mammary epithelial cells. Oncogene 22, 983-991 (2003).
28. Jiang, X., Chen, S., Asara, J. M. & Balk, S. P. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J. Biol. Chem. 285, 14980-14989 (2010).
29. Ueki, K. et al. Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J. Biol. Chem. 278, 48453-48466 (2003).
30. Gupta, S. C., Singh, R., Pochampally, R., Watabe, K. & Mo, Y. Y. Acidosis promotes invasiveness of breast cancer cells through ROS-AKT-NF-kappaB pathway. Oncotarget 5, 12070-12082 (2014).
31. Mayer, B. J. The discovery of modular binding domains: building blocks of cell signalling. Nat. Rev. Mol. Cell Biol. 16, 691-698 (2015).
32. Carnero, A. & Paramio, J. M. The PTEN/PI3K/AKT pathway in vivo, cancer mouse models. Front. Oncol. 4, 252 (2014).
33. Fruman, D. A. & Rommel, C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13, 140-156 (2014).
34. Worby, C. A. & Dixon, J. E. Pten. Annu. Rev. Biochem. 83, 641-669 (2014).
35. Ugi, S. et al. Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol. Cell Biol. 24, 8778-8789 (2004).
36. Cohen, P., Klumpp, S. & Schelling, D. L. An improved procedure for identifying and quantitating protein phosphatases in mammalian tissues. FEBS Lett. 250, 596-600 (1989).
37. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
38. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
39. Reddy, T. R., Tang, H., Xu, W. &Wong-Staal, F. Sam68, RNA helicase A and Tap cooperate in the post-transcriptional regulation of human immunodeficiency virus and type D retroviral mRNA. Oncogene 19, 3570-3575 (2000).
40. Westberg, C., Yang, J. P., Tang, H., Reddy, T. R. & Wong-Staal, F. A novel shuttle protein binds to RNA helicase A and activates the retroviral constitutive transport element. J. Biol. Chem. 275, 21396-21401 (2000).
41. Tang, H. & Wong-Staal, F. Specific interaction between RNA helicase A and Tap, two cellular proteins that bind to the constitutive transport element of type D retrovirus. J. Biol. Chem. 275, 32694-32700 (2000).
42. Stemke-Hale, K. et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 68, 6084-6091 (2008).
43. Ko, H. R. et al. P42 Ebp1 regulates the proteasomal degradation of the p85 regulatory subunit of PI3K by recruiting a chaperone-E3 ligase complex HSP70/CHIP. Cell Death Dis. 5, e1131 (2014).
44. Taniguchi, C. M. et al. The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res. 70, 5305-5315 (2010).
45. Cizkova, M. et al. PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer 13, 545 (2013).
46. Cortes, I. et al. p85beta phosphoinositide 3-kinase subunit regulates tumor progression. Proc. Natl Acad. Sci. USA 109, 11318-11323 (2012).
47. Li, L., Plummer, S. J., Thompson, C. L., Tucker, T. C. & Casey, G. Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk. Clin. Cancer Res. 14, 633-637 (2008).
48. Ito, Y., Hart, J. R., Ueno, L. & Vogt, P. K. Oncogenic activity of the regulatory subunit p85beta of phosphatidylinositol 3-kinase (PI3K). Proc. Natl Acad. Sci. USA 111, 16826-16829 (2014).
49. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
50. Huang, C. H. et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318, 1744-1748 (2007).
51. Amzel, L. M. et al. Structural comparisons of class I phosphoinositide 3-kinases. Nat. Rev. Cancer 8, 665-669 (2008).
52. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254 (1976).
53. Sambrook, J. & Russell, D. W. (eds. ). in Molecular Cloning: A Laboratory Manual. Ch. 8 Protocol 9, 8. 54-8. 60 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA, 2001).
54. Montague, T. G., Cruz, J. M., Gagnon, J. A., Church, G. M. & Valen, E. CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic Acids Res. 42, W401-W407 (2014).
55. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343-345 (2009).
56. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).
57. Si, M. L. et al. miR-21-mediated tumor growth. Oncogene 26, 2799-2803 (2007).